TOPICAL 1,25 VITAMIN D3 IN CHILDREN WITH PSORIASIS

银屑病儿童局部使用 1,25 维生素 D3

• 批准号: 6117215
• 负责人: MICHAEL F HOLICK
• 金额: $ 3.05万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117215
• 关键词: 1,25 dihydroxycholecalciferol; adolescence (12-20); cell growth regulation; clinical research; drug screening /evaluation; human subject; human therapy evaluation; middle childhood (6-11); outcomes research; preschool child (1-5); psoriasis; skin disorder chemotherapy; topical drug application; vitamin therapy

It has been shown that the active form of vitamin D3, 1,25-Dyhydroxyvitamin D3, has biological effects on human skin. Psoriasis is caused by abnormally rapid growth of skin cells. We have demonstrated that this vitamin D compound decreases the growth rate of normal cells in adults. We are interested in determining whether 1,25 (OH)2D3 is useful for treating psoriasis in children ages 4 through 18 years.

研究表明，维生素D3的活性形式1，25-二羟基维生素D3对人体皮肤具有生物效应。牛皮癣是由皮肤细胞异常快速生长引起的。我们已经证明，这种维生素D化合物会降低成人正常细胞的生长速度。我们感兴趣的是确定1，25(OH)2D3是否对治疗4至18岁儿童银屑病有效。